Novel cryoballoon technology for atrial fibrillation ablation: Impact of pulmonary vein variant anatomy, cooling characteristics, and 1-year outcome from the CHARISMA registry
Heart Rhythm · 2025
DOI: 10.1016/j.hrthm.2024.08.040 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Heart Rhythm, 2025. Verfasst von Marco Schiavone und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Electrophysiology & Cardiac Pacing, Centro Cardiologico Monzino, IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cryosurgery, Pulmonary Veins, Registries. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: No data have been reported on cooling characteristics and the impact of variant pulmonary vein (PV) anatomy on atrial fibrillation (AF) recurrences after POLARx cryoballoon (CB) ablation. OBJECTIVE: The purpose of this study was to analyze the impact of PV anatomy variants and cooling characteristics after CB ablation from a large multicenter prospective registry. METHODS: The primary end point was defined as 1-year absence of any atrial tachyarrhythmias (ATAs: AF/atrial flutter/atrial tachycardia). Correlation between ATA recurrences and anatomy variants/cooling characteristics were evaluated. The secondary outcome was the rate of major periprocedural complications. RESULTS: A total of 429 consecutive patients diagnosed with paroxysmal AF (83.4%) or persistent AF (peAF; 16.6%) were enrolled. Twenty-eight patients (6.6%) exhibited an anatomical variant (common ostium: 4.0%; adjunctive PV: 2.6%). Nadir temperature, thaw time, and total deflation time were different between standard PVs and PV variants. After the blanking period, over a mean of 431 ± 99 days of follow-up, 63 patients (14.7%) suffered an ATA recurrence. Patients with recurrences had both a shorter thaw time (18.5 ± 7 seconds vs 19.8 ± 7 seconds; P = .0012) and a shorter total deflation time, whereas time to isolation was longer (57.4 ± 42 seconds vs 49.1 ± 33 seconds; P = .04). Patients with anatomy variants showed a similar ATA recurrence rate (5 of 28 [17.9%]) to the standard PV anatomy group (58 of 401 [14.5%]) (P = .584), with a hazard ratio (HR) of 1.43 (95% confidence interval [CI] 0.49-4.13; log-rank, P = .4384). After adjusting for confounders, heart failure (HR 4.12; 95% CI 1.75-9.73; P = .0013) and peAF (HR 1.81; 95% CI 1.03-3.18; P = .0433) remained associated with ATA recurrence during follow-up. CONCLUSION: The POLARx CB system demonstrated long-term efficacy, along with a safe profile, in both patients with paroxysmal AF and those with peAF, regardless of the presence PV variants. Time to isolation was longer in patients with ATA recurrences during follow-up. CLINICAL TRIAL REGISTRATION: Catheter Ablation of Arrhythmias with a High-Density Mapping System in Real-World Practice (CHARISMA). CLINICALTRIALS: gov identifier: NCT03793998. Registration date: January 4, 2019.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Electrophysiology & Cardiac Pacing, Centro Cardiologico Monzino, IRCCS, Milan, Italy.
- Center of Excellence in Cardiovascular Sciences, Ospedale Isola Tiberina - Gemelli Isola, Rome, Italy.
- Boston Scientific, Milan, Italy.
- Laboratorio di Elettrofisiologia, Clinica San Michele, Maddaloni, Caserta, Italy.
- Electrophysiology Unit, Cardiovascular Department, Poliambulanza Institute Hospital Foundation, Brescia, Italy.
- Istituto di Cardiologia Università Cattolica del Sacro Cuore, Rome, Italy; Department of Cardiovascular Sciences, Arrhythmology Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.
Zitieren
APA
Schiavone, M., Bianchi, S., Malacrida, M., Fassini, G., Ricciolino, R., Pecora, D., Pelargonio, G., Iacopino, S., Ducceschi, V., Maggio, R., Bianchini, L., La Greca, C., Rossi, P., Bencardino, G., Moltrasio, M., Di Belardino, N., Pepi, P., Rossi, L., Santagostino, M., …, & De Simone, A. (2025). Novel cryoballoon technology for atrial fibrillation ablation: Impact of pulmonary vein variant anatomy, cooling characteristics, and 1-year outcome from the CHARISMA registry. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2024.08.040
Vancouver
Schiavone M, Bianchi S, Malacrida M, Fassini G, Ricciolino R, Pecora D, et al. Novel cryoballoon technology for atrial fibrillation ablation: Impact of pulmonary vein variant anatomy, cooling characteristics, and 1-year outcome from the CHARISMA registry. Heart Rhythm. 2025. doi:10.1016/j.hrthm.2024.08.040
BibTeX
@article{Schiavone2025,
author = {Schiavone, Marco and Bianchi, Stefano and Malacrida, Maurizio and Fassini, Gaetano and Ricciolino, Riccardo and Pecora, Domenico and Pelargonio, Gemma and Iacopino, Saverio and Ducceschi, Valentino and Maggio, Ruggero and Bianchini, Lorenzo and La Greca, Carmelo and Rossi, Pietro and Bencardino, Gianluigi and Moltrasio, Massimo and Di Belardino, Natale and Pepi, Patrizia and Rossi, Luca and Santagostino, Matteo and Tondo, Claudio and De Simone, Antonio},
title = {Novel cryoballoon technology for atrial fibrillation ablation: Impact of pulmonary vein variant anatomy, cooling characteristics, and 1-year outcome from the CHARISMA registry},
journal = {Heart Rhythm},
year = {2025},
doi = {10.1016/j.hrthm.2024.08.040}
}
EUVIMED